StockNews.AI
ANIK
StockNews.AI
116 days

Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025

1. Anika Therapeutics will release Q1 2025 financial results on May 9. 2. A conference call following the release will discuss business highlights. 3. Anika specializes in joint preservation and orthopedic care solutions. 4. They focus on osteoarthritis management and regenerative solutions. 5. Anika's financial performance could influence market perceptions.

Earnings
+0.38%Current Return
VS
+0.72%S&P 500
$14.37504/25 09:06 AM EDTEvent Start
$14.4304/28 09:14 AM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming earnings release typically creates investor anticipation; historical examples show positive earnings often lead to stock price increases.

How important is it?

The Q1 earnings release will provide insights into company's performance, impacting investor sentiment and stock price.

Why Short Term?

The earnings call is imminent, affecting short-term trading decisions but not necessarily long-term performance.

Related Companies

VRTXREGNMDT
April 25, 2025 09:00 ET  | Source: Anika Therapeutics Inc. BEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2025 financial results before the opening of the market on Friday, May 9, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 63463. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.anika.com. The call will be archived and accessible on the same website shortly after its conclusion. About Anika Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com. ANIKA, ANIKA THERAPEUTICS and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use. For Investor Inquiries:Anika Therapeutics, Inc.Matt Hall, 781-457-9554Director, Corporate Development and Investor Relationsinvestorrelations@anika.com

Related News